Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 5/20 | 1.00 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.79 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.54 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.54 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.54 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.54 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.54 |
| ▸ | HTR3B | O95264 | 1/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.54 |
| ▸ | CHRNG | P07510 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5378467 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL5389874 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| SCHEMBL29733346 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL31393035 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5373327 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5378422 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5380807 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5376224 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5378430 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 | |
| Hydrochloric Acid SCHEMBL5373324 | 0.98 | CHRNA7 (0.97) | CHRNA7CHRNB2CHRNA4ALDH1A1CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7214686-B2 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. (US) | 2007-05-08 | — | — | US | claimed |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | TARGACEPT, INC. | 2004-11-04 | — | — | US | claimed |
| EP-0994875-B1 | 3-PYRIDYL-1-AZABICYCLOALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | TARGACEPT INC (US) | 2004-03-10 | — | — | EP | claimed |
| CN-118666833-B | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-12-13 | — | — | CN | disclosed |
| CN-118666833-A | Preparation method of 2- (5-bromopyridine-3-yl) quinuclidine | 龙曦宁（上海）医药科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | BISCAYNE NEUROTHERAPEUTICS, INC. | 2015-07-09 | — | — | US | disclosed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-2409703-A1 | Treatment with alpha7-selective ligands | Targacept, Inc. (US) | 2012-01-25 | — | — | EP | disclosed |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| EP-2364150-A1 | TREATMENT WITH ALPHA 7-SELECTIVE LIGANDS | Targacept Inc. (US) | 2011-09-14 | — | — | EP | disclosed |
| US-6624173-B1 | Characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia) treated by | TARGACEPT, INC. | 2003-09-23 | — | — | US | disclosed |
| US-20030158211-A1 | Methods and compositions for treatment of central nervous system disorders | MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC. | 2003-08-21 | — | — | US | disclosed |
| WO-2003051302-A2 | METHODS AND COMPOSITIONS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TARGACEPT, INC. (US) | 2003-06-26 | — | — | WO | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
| US-6525065-B1 | Central nervous system disorders; administering an endo or exo form of a 1-aza-2-(3-pyridyl)bicyclo(2.2.1)heptane, or a 1-aza-7-(3-pyridyl)bicyclo(3.2.2) nonane, or a 1-aza-2-(3-pyridyl)bicyclo(2.2.2)octane | TARGACEPT, INC. | 2003-02-25 | — | — | US | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| EP-0994875-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
| WO-1999000385-A1 | 3-PYRIDYL-1-AZA-BICYCLO-ALKANE DERIVATIVES FOR PREVENTION AND TREATMENT OF CNS DISORDERS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150191430-A1 | CONJUGATES OF HUPERZINE AND ANALOGS THEREOF | HTT, HNMT, GAP43 | CHRNA7 50/4885CHRNB2 44/4885CHRNA4 68/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 3/4885 |
| US-20040220214-A1 | Pharmaceutical compositions and methods for effecting dopamine release | COMT, SLC6A3, PARK7 | CHRNA7 27/4885CHRNB2 16/4885CHRNA4 74/4885 |
| US-20030158211-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNA7 46/4885CHRNB2 17/4885CHRNA4 30/4885 |
| US-20110262407-A1 | TREATMENT WITH ALPHA7 SELECTIVE LIGANDS | CHRNA7, CHRNA4, CHRNA2 | CHRNA7 1/4885CHRNB2 6/4885CHRNA4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.